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Abstract
Background: Down syndrome (DS), caused by trisomy of human chromosome 21 (HSA21), is the most common
genetic cause of mental retardation in humans. Among complex phenotypes, it displays a number of neural pathologies
including smaller brain size, reduced numbers of neurons, reduced dendritic spine density and plasticity, and early
Alzheimer-like neurodegeneration. Mouse models for DS show behavioural and cognitive defects, synaptic plasticity
defects, and reduced hippocampal and cerebellar neuron numbers. Early postnatal development of both human and
mouse-model DS shows the reduced capability of neuronal precursor cells to generate neurons. The exact molecular
cause of this reduction, and the role played by increased dosage of individual HSA21 genes, remain unknown.
Results:  We have subcutaneously injected mouse pluripotent ES cells containing a single freely segregating
supernumerary human chromosome 21 (HSA21) into syngeneic mice, to generate transchromosomic teratomas.
Transchromosomic cells and parental control cells were injected into opposite flanks of thirty mice in three independent
experiments. Tumours were grown for 30 days, a time-span equivalent to combined intra-uterine, and early post-natal
mouse development. When paired teratomas from the same animals were compared, transchromosomic tumours
showed a three-fold lower percentage of neuroectodermal tissue, as well as significantly reduced mRNA levels for
neuron specific (Tubb3) and glia specific (Gfap) genes, relative to euploid controls. Two thirds of transchromosomic
tumours also showed a lack of PCR amplification with multiple primers specific for HSA21, which were present in the
ES cells at the point of injection, thus restricting a commonly retained trisomy to less than a third of HSA21 genes.
Conclusion:  We demonstrate that a supernumerary chromosome 21 causes Inhibition of Neuroectodermal
DIfferentiation (INDI) of pluripotent ES cells. The data suggest that trisomy of less than a third of HSA21 genes, in two
chromosomal regions, might be sufficient to cause this effect.
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Background
Down's syndrome (DS), caused by the trisomy of human
chromosome 21 (HSA21), [1] is a complex condition
characterized by a plethora of phenotypic features, most
striking of which are reduced neuron number and synap-
tic plasticity, early Alzheimer-like neurodegeneration,
craniofacial dysmorphia, heart development defects, and
powerful suppression of the incidence of most solid
tumours [2,3]. In the first few months of life, DS babies
display brachycephaly, microcephaly, delayed myelina-
tion, reduced growth of frontal lobes, a narrowing of the
superior temporal gyrus, diminished size of the brainstem
and cerebellum, and up to 50% reduction in numbers of
cortical granular neurons [4-6]. The exact timing of onset
of these changes is still unclear. In a limited study, neuro-
nal progenitor cells from 3 foetal DS brains showed a
reduced neuron number following further differentiation
in vitro, compared to euploid foetal cells [7]. Also, DS foe-
tal neural cells showed a reduced propensity for prolifera-
tion and survival in vitro compared to euploid controls
[8]. Tumours of neural tissues, such as neuroblastomas,
are comparatively very rarely observed in DS individuals
[9,10].
Mouse models for DS display, among other features,
behavioural and cognitive defects, synaptic plasticity
defects and long term potentiation (LTP) deficits in the
hippocampus, as well as reduced hippocampal and cere-
bellar neuron numbers [11-14]. The reduction of cerebel-
lar granule neuron numbers in mouse models occurs in
the first 10 days postnatally, due to a defective response to
Sonic hedgehog (Shh) [15], secreted by an already reduced
number of Purkinje neurons [11]. In the hippocampus,
the exact timing of the onset of neuronal precursor cell
reduction is less clear, but a reduced number of mitoti-
cally active granule neuron cell precursors is observed at
day P6 [16]. At 4–6 months of age, mice undergo a neuro-
degenerative reduction of basal forebrain cholinergic neu-
rons [17,18], further contributing to the reduction in
granule cell neuron numbers [19].
Three quarters of human trisomy 21 concepti die in utero
from developmental arrest [20], and phenotypic features
of DS are retained even in mosaic DS subjects [21], as well
as in transchromosomic DS mouse models where adult
tissues retain <50% trisomic cells, having started from a
fully trisomic conceptus [22,23]. This implies that many
phenotypic features of DS must be determined by events
occurring very early in development, but the exact nature
of these early events, and the role played by increased dos-
age of individual HSA21 genes remain unknown. In an
attempt to study the effects of trisomy 21 on the capacity
of pluripotent embryonic stem (ES) cells to proliferate
and differentiate in vivo, we report here the use of a mouse
pluripotent embryonic stem (ES) cell line with a freely
segregating HSA21 as a single supernumerary chromo-
some [24], in the generation of transchromosomic terato-
mas upon subcutaneous injections into syngeneic mice.
Results
Generation of teratomas
The cell line (47-1), generated by introduction of a single
HSA21 into the mouse ES cell line D3, was found by PCR
amplification of human specific markers to contain virtu-
ally all of the gene content of HSA21, and was shown not
to contain DNA from any human chromosome other than
HSA21 [24]. Transchromosomic 47-1 and control D3 cell
lines were cultured under identical conditions and veri-
fied at the point of injection to be undifferentiated, having
similar proliferation indices, and showing the presence of
HSA21 in practically all 47-1 cells, and absence in D3 cells
[see Additional files 1 &2]. Integrity of the retained HSA21
was verified by human specific PCR of 33 markers, and
RT-PCR of 8 HSA21 genes. In 3 independent experiments
(each starting from a new batch of frozen cells and follow-
ing the entire experimental design as outlined in [see
Additional file 1], a total of 30 mice were injected subcu-
taneously, each with 47-1 cells into the left flank, and D3
cells into the right flank. The resulting subcutaneous
tumours were harvested 30 days later resulting in n = 24
mice - (left flanks, 47-1 injection point) and n = 21 mice
(right flanks, D3 injection point). Sixteen animals devel-
oped tumours in both flanks. No significant difference in
size/weight was found between 47-1 and D3 tumours (see
Additional file 3). All tumours grew as solitary (single
tumour per injection point) spheroid masses in the sub-
cutaneous tissue, clearly separated from host tissues by an
envelope of connective-like tissue.
Histological analysis of the teratomas
Qualitative histological analysis of standard H&E stained
tumour sections revealed a multitude of different cell
types in all tumours. Scattered islands of many tissue types
were observed including: keratinized squamous epithe-
lium, ciliated epithelium, glandular epithelium, acini of
salivary glands, smooth muscle, cartilage, bone, haemat-
opoietic tissue, fat tissue and undifferentiated tissue.
Many tumour slices lacked the presence of differentiated
neuroectodermal tissue.
Tumour sections were analyzed quantitatively, by a his-
topathologist blinded to the tumour origin, for the pres-
ence and relative abundance (%) of four types of tissue:
neuroectodermal, mesenchymal, epithelial and undiffer-
entiated (Fig. 1A). Transchromosomic tumours showed
an approximately three-fold lower mean percentage of
neuroectodermal tissue, both when compared across all
tumours (highly significant by two tailed t-test (p =
0.004), and when compared strictly within pairs of
tumours which grew in the same animal (n = 16 pairs,BMC Developmental Biology 2007, 7:131 http://www.biomedcentral.com/1471-213X/7/131
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paired t-test, p = 0.037), (Fig. 1B). The transchromosomic
tumours also showed an almost two fold reduction of
mRNA for mouse Tubb3, a neuron specific gene (Fig. 1C;
t-test, p = 0.007, paired t-test p = 0.111 but non-overlap-
ping standard error bars), and a three-fold reduction of
mouse Gfap mRNA, a glia specific gene (Fig. 1D; t-test, p =
0.00001, paired t-test p = 0.003). The presence of both
neurons and astroglia cells, respectively, within the
tumours has been verified by immunofluorescence using
antibodies against MAP2 and GFAP, which confirmed the
Histology of wildtype and transchromosomic tumours and Inhibition of Neuroectodermal tissue DIfferetiation (INDI) by the  supernumerary HSA21 Figure 1
Histology of wildtype and transchromosomic tumours and Inhibition of Neuroectodermal tissue DIfferetiation 
(INDI) by the supernumerary HSA21. A freely segregating HSA21 has been introduced into the mouse ES cell line D3 to 
generate a transchromosomic line, 47-1, with an effective trisomy of the gene content of the entire HSA21. D3 and 47-1 cells 
were cultured in an undifferentiated state, under identical conditions, and verified at the point of injection to retain an appar-
ently intact copy of HSA21 in practically all 47-1 cells and no D3 cells [see Additional file 1 & 2]. Thirty syngeneic mice were 
each injected subcutaneously with an identical inoculum of between 5–6.5 million 47-1 cells in the left flank, and the same 
number of D3 cells in the right flank. Resulting tumours were harvested 30 days post injection [experimental design see Addi-
tional file 1]. A, morphological classification of tissue types present in a typical pair of tumours which grew in the same mouse; 
D3 (left column, panels i, iii, v, vii) and 47-1 (right column, panels ii, iv, vi, viii). (i) and (ii) are representative sketches of (iii) and 
(iv), respectively. Note the absence of neuroectodermal tissue in the 47-1 tumour. B, the average neuroectoderm contents of 
all D3 and 47-1 tumours, and of D3 and 47-1 tumour pairs which grew in the same mouse (paired tumours, n = 16 pairs), as 
determined by analysis of H&E sections by a histopathologist blinded to the origin of the tumours. C, the average levels of 
Tubb3 mRNA expression (normalised to Gapdh mRNA levels) in all D3 and 47-1 tumours, and in D3 and 47-1 tumour pairs 
which grew in the same mouse, as determined by real-time quantitative RT-PCR; D, the average levels of Gfap mRNA expres-
sion (normalised to Gapdh mRNA levels) in all D3 and 47-1 tumours, and in D3 and 47-1 tumour pairs which grew in the same 
mouse, as determined by real-time quantitative RT-PCR.
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observation of the reduced numbers of both types of cells
in the transchromosomic tumours, compared to controls
(Fig. 2).
Analysis of a HSA21 region causing Inhibition of 
Neuroectodermal DIfferentiation (INDI)
Genomic DNA and total RNA of 47-1 tumours were ana-
lysed by PCR and RT-PCR, respectively, using the same
battery of human sequence specific markers/genes that
were verified to be present in the 47-1 cell line at the point
of injection [see Additional file 1 and Fig. 3]. Two thirds
of all 47-1 tumours showed a lack of amplification with
multiple primers in the regions distal to PRSS7, proximal
to TTC3, and distal to CSTB (Fig. 3). In the deleted seg-
ments, both genomic DNA and ubiquitously expressed
cDNA markers failed to amplify. The percentage of cells
within each tumour that might have lost the entire HSA21
were estimated by quantitative genomic DNA real-time
PCR using a single marker within the commonly retained
chromosomal segments normalized to a single mouse
genomic DNA locus. An average level of 76% (+/- 8%)
was obtained for retention of HSA21 in DNA material
extracted from the 47-1 tumours. As there were sufficient
numbers of cells of many different tissue types in all
tumours, and multiple HSA21 PCR markers in the deleted
regions gave no amplified product, deletions must have
occurred before any differentiation of ES cells in the
tumours took place. The presence or absence of deletions
Neurons and astroglia in a pair of wildtype and transchromosomic teratomas from the same animal Figure 2
Neurons and astroglia in a pair of wildtype and transchromosomic teratomas from the same animal. The pres-
ence of the two main cell types of the differentiated neuroectoderm, neurons and astroglia, within the tumours was visualised 
by fluorescence immunocytochemistry. Paraffin-embedded sections of wildtype (D3) and transchromosomic (47-1) tumours 
were stained with antibodies specific for neuronal (MAP-2), and glial (GFAP) proteins. Transchromosomic tumours contained 
far fewer glia and neurons than wildtype tumours. A, D3 tumour at low magnification; B, high magnification photo of the same 
D3 tumour; C, 47-1 tumour at low magnification; D, high magnification photo of the same 47-1 tumour.
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Mapping of HSA21 deletions in DNA and RNA from transchromosomic tumours Figure 3
Mapping of HSA21 deletions in DNA and RNA from transchromosomic tumours. DNA and total RNA isolated 
from transchromosomic tumours were subjected to PCR or RT-PCR analyses, respectively, to determine the retention of 
each of 42 HSA21-specific markers in the transchromosome in the tumours. Shown on the right are the positions of markers 
relative to genes, and they correspond to the HSA21 STS markers analysed, listed on the left. cDNA markers are shown in 
bold text. PCR and RT-PCR analyses of DNA and RNA, respectively, isolated from D3 and 47-1 ES cell lines at the point of 
injection (first 2 columns, highlighted as red font) confirmed the full retention of HSA21 in 47-1 ES cells. No HSA21 markers 
were amplified in DNA or mRNA/cDNA from the D3 mouse control cell line. Markers in the 'INDI' regions that were com-
monly retained in all transchromosomic tumours are highlighted by green background. White box = no amplified product 
observed by agarose gel after 40 PCR cycles, black box = amplified product observed by agarose gel.
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did not correlate with experimental chronology, or per-
centages of tissue types including neuroectoderm (not
shown). This suggests that deletions most likely occurred
during the initial cell divisions in undifferentiated ES cells
at the very start of tumour growth. When only the deleted
47-1 tumours were compared to either all D3 tumours, or
only their direct pairs, the statistically significantly
reduced percentage of neuroectoderm, and levels of Tubb3
and  Gfap, were observed, virtually identical to graphs
shown in Fig 1. Regardless of the cause of the deletions,
the data open themselves to interpretation that the seg-
mental trisomy common to all tumours (Fig. 4), compris-
ing less than a third of HSA21 gene complement, might be
sufficient to cause a powerful Inhibition of Neuroectoder-
mal DIfferentiation (INDI) in pluripotent ES cells in vivo.
Discussion
The undifferentiated ES cell inoculates were allowed to
develop for 30 days, equivalent to the time span of entire
intrauterine, and 10 postnatal days of mouse develop-
ment. This extended period encompasses the critical inter-
val (P0–P6), in which the biggest difference in neuronal
precursor cell proliferation was observed between mouse
models of DS, and their euploid littermate controls
[11,15,16]. The use of syngeneic inbred mouse strains
also minimizes the individual variation, which is further
reduced by the paired analysis of tumours which grow in
the same recipient animal. Using this system, we have
observed a powerful inhibition of neuroectodermal fate
in transchromosomic +HSA21 containing pluripotent
mouse ES cells, compared to their parental control (Fig
1A,B.). This conclusion is not without caveats: the inhibi-
tion of neural fate could be specific to the cell line used,
or it could be related to the sheer presence of a supernu-
merary chromosome, not specific to HSA21. Though it is
impossible to rule out these caveats at this stage, we
believe on balance of probabilities, that this system shows
a measurable phenotype with potential to map it to a seg-
ment of HSA21. The reduced Tubb3 levels (Fig 1C) clearly
indicate a reduction in mature neuron numbers in tri-
somic teratomas, confirmed by neuron specific staining
(Fig 2). The reduction in GFAP levels could be partly the
result of reduced numbers of mature astrocytes, as well as
reduced numbers of neuronal precursors, corresponding
to GFAP+ cells found in the subgranular zone and hilus
[25]. These GFAP+ precursors divide and give rise to
immature neurons (DCX+PSA-NCAM+) [25]. Radial glial
cells, which are the main source of precursors for neuro-
genesis in the dentate gyrus, also express GFAP [26]. These
very cellular layers are the site of the biggest deficit in
mitotic activity at postnatal day 6 in mouse models of DS
[16].
Spontaneous deletions of the supernumerary HSA21 were
observed in two thirds of transchromosomic tumours (Fig
3). As there were sufficient numbers of cells of many dif-
ferent tissue types in all tumours, and multiple HSA21
PCR reactions (including RT-PCR of ubiquitously
expressed HSA21 genes) were negative in the deleted
A schematic diagram showing the boundaries of retained  regions of HSA21 in transchromosomic teratomas, and their  relationship to trisomic regions in mouse models of DS Figure 4
A schematic diagram showing the boundaries of 
retained regions of HSA21 in transchromosomic ter-
atomas, and their relationship to trisomic regions in 
mouse models of DS. The two regions labelled "INDI" 
were commonly retained by all tumours. As there were suffi-
cient numbers of cells of many different tissue types in all 
tumours, and multiple HSA21 PCR markers were negative in 
the deleted regions, deletions must have occurred before any 
differentiation of ES cells in the tumours took place. The 
regions of the HSA21 gene map which are trisomic in some 
of the current segmental trisomy mouse models are indi-
cated on the right by vertical lines, for comparison.
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regions, deletions must have occurred before any differen-
tiation of ES cells in the tumours took place, probably
during the early cell divisions at the very start of tumour
growth. Alternatively, a subset of cells with a major dele-
tion might have been present within the inoculum of 47-
1 cells; a less likely explanation, as 3 independent cultures
gave rise to a similar proportion of tumours with, and
without deletions. We cannot exclude the possibility that
the inocula in all 3 experiments contained a mixture of
two clones, the 47-1, and a segmental trisomy clone.
However, the deleted segments also show subtle varia-
tions in the pattern of markers present, making this possi-
bility less likely. Whether the deletions are caused by an
instable DNA sequence element, and whether or not they
provide a selective advantage to the proliferation of cells,
remains to be investigated. Regardless of the cause of dele-
tions within the tumours, they had no effect on the statis-
tical significance of any differences shown in Fig. 1.
Though the data are not conclusive on this point, it can be
hypothesized that the segmental trisomy of two regions
common to all tumours (Fig. 4), comprising less than a
third of the HSA21 gene complement, could be sufficient
to cause a powerful Inhibition of Neuroectodermal DIffer-
entiation (INDI) in pluripotent ES cells in vivo.
The telomeric INDI region partially overlaps with trisomic
regions in mouse segmental trisomy models for DS, such
as Ts65Dn and Ts1Cje (Fig. 4), which both have a reduced
number of granular layer neurons in the cerebellum and
hippocampus, compared to euploid littermates
[11,16,27]. The overlap between the telomeric INDI seg-
ment and the 3 mouse models shown in Fig. 4. is
restricted to 23 genes (based on comparisons, see refs
[1,28]. The centromeric INDI region is less likely to play a
causative role in INDI, as the degree of cerebellar neuron
number reduction is similar between the Tc1 mouse
model [23] which has this region in trisomy, and the
Ts65Dn and Ts1Cje models that do not [1]. The exception
are only 3 genes from the centromeric INDI region (BTG3,
YG81 and PRSS7) which are deleted in the third chromo-
some of the Tc1 model [23], and therefore remain
unchecked. The telomeric INDI segment of 23 genes over-
lapping with trisomic mouse models is fully contained
within the Ts1Rhr, the 33 gene-trisomy mouse model,
which does not show the reduction in cerebellar volume,
or neuron density [28]. This mouse model also shows no
hippocampal volume change, and no electrophysiologi-
cal and behavioural defects associated with hippocampal
functions, therefore suggesting that trisomy of this seg-
ment is not sufficient to cause the brain pathology in the
mouse [28]. However, this 33 gene segment was found
necessary for most of the cerebellar and hippocampal
pathology of Ts65Dn model, as when its trisomy is
reversed to disomy, the pathologies disappeared [28].
This segment also probably contains highly and bi-direc-
tionally dose sensitive genes regulating brain develop-
ment, as a monosomy of this segment (mouse model
Ms1RhR) produces striking changes in cerebellar and hip-
pocampal volume and neuron density [28]. The data in
our system could differ from those in the Ts1RhR model
due to the human, rather than mouse, origin of the third
chromosome. Interestingly, very recent data in human DS
show that duplication of a 4.3 Mb segment, completely
contained within the 33 gene equivalent segment in the
mouse, is sufficient to cause (in three members of the
same family) a range of DS phenotypes, including brach-
ycephaly, intellectual disability, mental retardation,
speech learning impairment, and a typical facial gestalt of
DS [29]. Our data suggest that further studies of individ-
ual gene dosage effects within the INDI region could
reveal major candidate contributors to DS-related hypo-
cellularity of the CNS, and suppression of neuroblasto-
mas.
Conclusion
We demonstrate that a supernumerary chromosome 21
causes Inhibition of Neuroectodermal DIfferentiation
(INDI) of pluripotent ES cells. The data open themselves
to interpretation that the trisomy of less than a third of
HSA21 genes, in two chromosomal regions, could be suf-
ficient to cause this effect.
Methods
General outline of the experimental design is summarized
[see Additional file 1].
ES cell lines and culture
The transchromosomic cell line 47-1, described in a previ-
ous publication [24], has been produced by tagging
HSA21 with a Neomycin resistance marker, and introduc-
ing the tagged chromosome into a mouse embryonic stem
cell line D3, using microcell mediated chromosome trans-
fer. ES cells were grown on a layer of mitotically inacti-
vated mouse embryonic fibroblasts (feeder cells), in
medium supplemented with LIF (ESGRO). ES medium:
DMEM, 15% FCS, 25,000 U Pen/Strep, L-Glutamine,
non-essential amino acids, β-mercaptoethanol, 5 × 105
U/ml LIF. 47-1 ES cells were also grown in the presence of
G418 (500 mg/ml), until one passage before they were
harvested for injections. During this last passage the G418
was removed, so that the 47-1 and D3 cells had identical
culturing conditions. At the point of injection, aliquots of
both cell suspensions have been verified by phase contrast
microscopy to contain morphologically undifferentiated
cells, with similar proliferation indices, as measured by
visualizing the cells in mitosis using a Phosphohistone
H3-specific antibody [see Additional file 2]. One aliquot
each of the 47-1 and D3 ES cells was cultured without
feeders for one passage, and interphase nuclei were pre-
pared for FISH using a HSA21-specific centromeric probeBMC Developmental Biology 2007, 7:131 http://www.biomedcentral.com/1471-213X/7/131
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pZ21A, and standard protocol for interphase nuclei FISH
[30]. HSA21 retention was confirmed in 96/100 exam-
ined 47-1 cells, and 0/100 D3 [see Additional file 2].
Injections and tumour utilization
The use of mice was approved by the institutional ethics
committee, and by the Home Office project licence (PPL
70/5714). ES cells were trypsinised, washed twice in ster-
ile 1× PBS and resuspended at a density of 6.5 × 106 cells/
200 μl (experiment 1), or 5 × 106 cells/200 μl (experi-
ments 2 and 3) immediately before injections. Equal
numbers of cells in 200 μl of D3 and 47-1 ES cell suspen-
sions were subcutaneously injected into the right and left
flanks respectively of each of a total of 30 male 129/Sv
mice. Mice were monitored every two days for tumour
growth (assessed by palpation and measurement with cal-
lipers). At 30 days post-injection, mice were sacrificed and
tumours removed. Each tumour was cut in half. One half
was placed in 10% buffered formalin and the other half
snap-frozen in liquid nitrogen. Snap-frozen tumour
halves were ground into powder before extracting total
RNA and DNA. RNA extraction was carried out using
RNABee (Biogenesis) in accordance with the manufac-
turer's protocol. DNA was extracted using 5% Chelex
(Sigma) suspension.
Histopathological analysis
Paraffin-embedded blocks of each tumour were cut in 3
μm thick sections and stained with H&E using standard
protocols. Sections were analysed by a histopathologist
blinded to the origin of the tumours, for the relative abun-
dance of four types of tissue: neuroectodermal, mesenchy-
mal, epithelial and undifferentiated, expressed as the
percentage of the total tumour slice, as demonstrated with
an example for a pair of tumours in Fig. 1A.
Immunofluorescent staining
Cytospins of D3 and 47-1 ES cell suspensions remaining
from injections in experiment 1 were fixed with 2% PFA
and stained with antibody specific for Phospho-Histone
H3 (1:1000) to determine ES cell viability at the point of
injection. Alexa Fluor 594 (Molecular probes) was used a
secondary antibody (1:800). Paraffin sections of tumours
were stained with anti-GFAP rabbit polyclonal
(DAKO,1:1000) and anti-MAP-2 monoclonal (Chemi-
con,1:500) antibodies, and visualised with Alexa Fluors
488 and 594 respectively (Molecular probes, 1:800).
Immunofluorescently stained cells and tumour sections
were viewed using a Zeiss Axioskop and the Quips Smart-
capture Imaging Software (Vysis).
Quantitative RT-PCR for tissue specific markers
Expression levels of mouse Tubb3 and mouse Gfap
mRNAs were assessed by real-time PCR in an ABI 7700
system, using SYBR Green as the reporter dye and mouse
Gapdh as the endogenous normalizing control. Primers
for real-time PCR were designed using Primer Express soft-
ware (ABI). Tubb3 primers: 300 nM FWD/300 nM REV
(GCTGTCCGCCTGCCTTTT/GACCTCCCAGAACTT-
GGCC). Gfap primers: 900 nM FWD/300 nM REV
(GAAAACCGCATCACCATTCC/TCGGATCTGGAGGTT-
GGAGA).  Gapdh  primers: 300 nM FWD/50 nM REV
(CCAGAAGACTGTGGATGGC/TGAGCTTCCCGT-
TCAGCTC). Normalized mRNA levels were calculated
using the standard curve method.
Assessment of integrity of HSA21 in the transchromosomic 
tumours
For mapping of the HSA21 retention in 47-1 tumours, STS
primer sequences were obtained from the UniSTS data-
base [31]. The ubiquitous expression of HSA21 cDNA
markers was determined from assessment of the Unigene
database [32], and data from expression catalogue studies
of HSA21 genes [33,34]. DNA and cDNA primers were
designed to be human specific in at least two of the most
3' bases. The exact sequences and conditions for each
primer set are available on request.
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tone H3 analysis of proliferation rates of 47-1 and D3 ES cells. A, 47-
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probe, pZ21A; (i) 47-1 cells showed specific signal with the probe in 96/
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D3 ES cell suspensions from the point of injection; D3 and 47-1 cells were 
shown have similar proliferation indices (as determined by a 2-tailed Stu-
dent's t-test)
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Additional file 3
Teratoma weights. Weights of 47-1 tumours and their D3 counterparts 
(where present) which grew in the same injected animal.
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